Literature DB >> 32951614

Acanthamoeba spp. monoclonal antibody against a CPA2 transporter: a promising molecular tool for acanthamoebiasis diagnosis and encystment study.

Michele Martha Weber-Lima1, Bianca Prado-Costa1, Alessandra Becker-Finco1, Adriana Oliveira Costa2, Philippe Billilad3, Cinthia Furst4, Juliana Ferreira de Moura1, Larissa Magalhães Alvarenga1.   

Abstract

Free-living amoeba of the genus Acanthamoeba are ubiquitous protozoa involved in opportunistic and non-opportunistic infection in humans, such as granulomatous amoebic encephalitis and amoebic keratitis. Both infections have challenging characteristics such as the formation of the resistant cysts in infected tissues, hampering the treatment and most usual diagnosis depending on time-consuming and/or low sensitivity techniques. The use of monoclonal antibodies presents itself as an opportunity for the development of more effective alternative diagnostic methods, as well as an important and useful tool in the search for new therapeutic targets. This study investigated the possibility of using a previously produced monoclonal antibody (mAb3), as a diagnostic tool for the detection of Acanthamoeba trophozoites by direct and indirect flow cytometry and immunofluorescence. Immunoprecipitation assay and mass spectrometry allowed the isolation of the antibody's target and suggested it is a transporter part of the CPA (cation: proton antiporter) superfamily. In vitro tests indicate an important role of this target in Acanthamoeba's encystment physiology. Our results support the importance of studying the role of CPA2 transporters in the context of acanthamoebiasis, as this may be a way to identify new therapeutic candidates.

Entities:  

Keywords:  Acanthamoeba; CPA2 transporters; diagnosis; encystment; flow cytometry; monoclonal antibody

Mesh:

Substances:

Year:  2020        PMID: 32951614     DOI: 10.1017/S0031182020001778

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  6 in total

1.  Specific Detection of Acanthamoeba species using Polyclonal Peptide Antibody Targeting the Periplasmic Binding Protein of A. castellanii.

Authors:  Min-Jeong Kim; Fu-Shi Quan; Hyun-Hee Kong; Jong-Hyun Kim; Eun-Kyung Moon
Journal:  Korean J Parasitol       Date:  2022-04-20       Impact factor: 1.776

Review 2.  Monoclonal Antibodies and Invasive Aspergillosis: Diagnostic and Therapeutic Perspectives.

Authors:  Xihua Lian; Amy Scott-Thomas; John G Lewis; Madhav Bhatia; Sean A MacPherson; Yiming Zeng; Stephen T Chambers
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

3.  Characterization of a Peptide Antibody Specific to the Adenylyl Cyclase-Associated Protein of Acanthamoeba castellanii.

Authors:  Min-Jeong Kim; Hae-Ahm Lee; Fu-Shi Quan; Hyun-Hee Kong; Eun-Kyung Moon
Journal:  Korean J Parasitol       Date:  2022-02-23       Impact factor: 1.341

4.  A history of over 40 years of potentially pathogenic free-living amoeba studies in Brazil - a systematic review.

Authors:  Natália Karla Bellini; Otavio Henrique Thiemann; María Reyes-Batlle; Jacob Lorenzo-Morales; Adriana Oliveira Costa
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-07-01       Impact factor: 2.747

5.  Stimulation of Acanthamoeba castellanii excystment by enzyme treatment and consequences on trophozoite growth.

Authors:  Zineb Fechtali-Moute; Philippe M Loiseau; Sébastien Pomel
Journal:  Front Cell Dev Biol       Date:  2022-09-12

6.  A Novel Monoclonal Antibody 1D2 That Broadly Inhibits Clinically Important Aspergillus Species.

Authors:  Xihua Lian; Amy Scott-Thomas; John G Lewis; Madhav Bhatia; Stephen T Chambers
Journal:  J Fungi (Basel)       Date:  2022-09-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.